This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sun Pharmaceutical Industries Ltd.
Drug Names(s): aminolevulinic acid (ALA), Levulan Kerastick
Description: Levulan Kerastick is a photosensitizer designed to be use with light sources, such as the Company's BLU-U Blue Light Photodynamic Therapy. Levulan Kerastick consists of aminolevulinic acid (ALA) which is converted to protoporphyrin IX (PpIX), a photosensitizer. When exposed to blue light, the accumulated PpIX produces a photodynamic reaction, creating superoxide and hydroxyl free radicals that are toxic to cells exposed to ALA.
DUSA and Stiefel
In January 2006, DUSA announced that it has entered into an exclusive marketing, distribution and supply agreement for Latin America with Stiefel Laboratories. The agreement has an initial term of ten years and covers current and future uses of DUSA's proprietary Levulan Kerastick for photodynamic therapy (PDT) in dermatology.
In September 2010, DUSA gave notice to Stiefel Laboratories, terminating the parties' Marketing, Distribution and Supply Agreement.
DUSA and Daewoong
In January 2007, DUSA entered into an exclusive marketing, distribution and supply agreement for certain Asian territories with Daewoong Pharmaceutical. The agreement has an initial term of ten years and covers current and future uses of DUSA's Levulan Kerastick for PDT in dermatology.
Daewoong will make up to $3,500,000 in milestone payments, based upon contract execution, approval of the product from regulatory authorities, and achievement of pre-determined...See full deal structure in Biomedtracker
Partners: Daewoong Pharmaceutical Company Ltd.
Levulan PDT News
Additional information available to subscribers only: